Back

Oral low-dose rapamycin treatment prevents aortic aneurysms in marfan mice

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Mechanisms of thoracic aortic disease and their treatment Pathophysiology and Mechanisms ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Marcin Zaradzki

University Hospital Heidelberg, Heidelberg (Germany)

5 More presentations in this session

Presentation thumbnail
PI 3-kinase/AKT/FOXO1 signaling in smooth muscle cells protects against abdominal aortic aneurysm
Doctor M. Vantler (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Mechanosensitive Ion Channel Piezo1 regulates tight junctions between endothelium and mediates the occurrence of aortic dissection
Doctor P. Teng (Hangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Comparative insights into type non-A non-B vs type B acute aortic syndromes and their blood pressure management: a monocentric, retrospective, 11-year study
Doctor F. Burgazzi (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Cardiovascular health in women with turner's syndrome: a 3-year single centre audit
Miss R. Macrae (London, GB)
Abstract Slides Video
Presentation thumbnail
Efficacy of beta blockers in patients with thoracic aortic aneurysm: meta-analysis of randomized controlled trials
Assistant Professor L. Tanriverdi (Malatya, TR)
Abstract Slides Video

Access the full session

Session thumbnail
Mechanisms of thoracic aortic disease and their treatment

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Exploration of cyclophilin A antibody anti-eCypA as a new approach in the treatment of marfan syndrome
thumbnail
Congress Presentation
Targeting MEK signalling with PD0325901 halts aortic dilatation and wall stiffening in a murine model of thoracic aortic aneurysm
thumbnail
Congress Presentation
Exploring adventitial pericyte dysfunction and MEK/ERK signalling as therapeutic targets in thoracic aortic aneurysm

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources